Healius Ltd
HLS: XASX (AUS)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| — | — | — | LOCK|Wb<X^w |
Healius Earnings: Shares Undervalued as Market Demands Faster Margin Turnaround
Healius' fiscal 2025 underlying pathology EBIT fell 5% to AUD 32 million on 6% revenue growth, but was weighed on by increased headcount. The firm's guidance was for softer fiscal 2026 revenue growth of 5%, but reiterated it expects group EBIT margins to recover to high single digits by fiscal 2027.
